Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells

Cancer Research

Volumn 56, Issue 13, 1996, Pages 2886-2890

  Reznikoff, Catherine A ^a,b,c   Yeager, Thomas R ^b   Belair, Cassandra D ^b   Savelieva, Elena ^c   Puthenveettil, Jairaj A ^b   Stadler, Walter M ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL TRANSFORMATION; CHROMOSOME 9P; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENESCENCE; WART VIRUS;

CARRIER PROTEINS; CELL AGING; CELL CYCLE; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; HUMANS; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; URINARY TRACT;

EID: 0029890863     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Knowles, M A., Elder, P. A., Williamson, M, Cairns, J. P. Shaw, M. E., and Law, M. G. Allelotype of human bladder cancer. Cancer Res , 53: 1230-1232, 1994.
2. Cairns, P., Shaw, M. E., and Knowles, M. A. Initiation of bladder cancer may involve deletion of a tumour suppressor gene on chromosome 9. Oncogene, 8: 1083-1085, 1993.
3. Ruppert, J. M., Tokino, K., and Sidransky, D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res., 53: 5093-5095, 1993.
4. Williamson, M. P., Elder, P. A., Shaw, M. E., Devlin, J., and Knowles, M. A. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet., 4: 1569-1577, 1995.
5. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletions at p16/CDKN2 in primary human tumors. Nat. Genet., 11: 210-212, 1995.
6. Stadler, W. M., and Olopade, O. I. The 9p21 chromosomal region in bladder cancer. Large homozygous deletions inactivate the CDKN2, CDKN2B, and MTAP genes. Urol. Res., in press, 1996.
7. Gonzalez-Zulueta, M., Shibata, A , Ohneseit, P. F., Spruck, C. H., III, Busch, C , Shamaa, M., Elbaz, M., Nichols, P. W., Gonzalgo, M L., Malmström, P-E., and Jones, P. A. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J. Natl Cancer Inst., 87: 1383-1393, 1995.
8. Serrano, M., Hannon, G. J., and Beach, D. A. New regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
9. Serrano, M., Gomez-Lahoz, E., Depinho, R. A., Beach, D., and Bar-Sagi, D. Inhibition of ras-induced proliferation and cellular transformation by p16ink4. Science (Washington DC), 267 249-252, 1995.
10. ink4 gene mediated by an adenovirus vector. Cancer Res., 55: 3250-3253, 1995.
11. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb Cancer Res., 54: 6078-6082, 1994.
12. Nevins, J. R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (Washington DC), 258: 424-429, 1992.
13. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., and Liu, Q A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994
14. Gruis, N. A., Weaver-Feldhaus, J., Liu, Q , Frye, C., Eeles, R., Orlow, I., Lacombe, L., Ponce-Castaneda, V., Lianes, P , Latres, E., Skolnick, M., Cordon-Cardo, C., and Kamb, A. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol., 146: 1199-1206, 1995.
15. Olopade, O. I., Pomykala, H F., Hagos, F., Sveen, L., Espinosa, R , Dreyling, M., Gursky, S., Stadler, W. M., LeBeau, M. M., and Bohlander, S. K. Construction of a 2.8 megabase YAC contig and cloning of the Methylthioadenosine phosphorylase (MFAP) gene from the tumor suppressor locus on 9p21. Proc Natl. Acad. Sci. USA, 92: 6489-6493, 1995.
16. Cairns, P., Mao, L., Merlo, A , Lee, D. J., Schwab, D., and Eby, Y. Rates of p16 (MTS1) mutations in primary tumors with chromosome 9 loss. Science (Washington DC), 265: 415-416, 1994.
17. Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, T., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. Y., Youl, P., Zone, J. J., Skolnick, M. H., and Cannon-Albright, L. A. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet., 8: 22-26, 1994.
18. ink4 mutations. N. Engl. J. Med , 333: 970-974, 1995.
19. Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., and Frants, R. R. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat. Genet., 10: 351-352, 1995
20. Yeager, T , Stadler, W., Belair, C., Puthenveettil, J., Olopade, O., and Reznikoff, C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55: 493-497, 1995.
21. Tam, S W., Shay, J. W., and Pagano, M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16ink4. Cancer Res., 54: 5816-5820, 1994.
22. cdkn2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol., 16: 859-867, 1996.
23. Reznikoff, C A., Belair, C., Savelieva, E., Zhai, Y., Pfeifer, K., Yeager, T., Thompson, K. J., De Vries, E., Bindley, C., Newton, M., Sekhon, G., and Waldman, F. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev., 8: 2227-2240, 1994.
24. Reznikoff, C. A., Loretz, L. J., Pesciotta, D. M., Oberley, T. D., and Ignjatovic, M. M. Growth kinetics and differentiation in vitro of normal human uroepithelial cells on collagen gel substrates in defined medium J. Cell Physiol., 131. 285-301, 1987.
25. Christian, B. J , Loretz, L. J , Oberley, T. D., and Reznikoff, C. A. Characterization of human uroepithelial cells immortalized in vitro by simian virus 40. Cancer Res., 47: 6066-6073, 1987.
26. Belair, C. D., Blelloch, R. H., and Reznikoff, C. A. Immortalization of human uroepithelial cells by human papilloma virus 16 E6 or E7 Radiat. Oncol. Invest., in press, 1996
27. Reznikoff, C. A , Loretz, L J., Johnson, M. D., and Swaminathan, S Quantitative assessments of the cytotoxicity of bladder carcinogens towards cultured normal human uroepithelial cells. Carcinogenesis (Lond.), 7: 1625-1632, 1986.
28. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I , Pereira-Smith, O., Peacocke, M., and Campisi, J. A novel biomarker identifies senescent human cells in culture and in aging skin in vivo Proc. Natl. Acad. USA, 92: 9363-9367, 1995.
29. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
30. Greaves, M. Is telomerase activity in cancer due to selection of stem cells and differentiation arres? TIG (Trends Genet.), 12: 127-128, 1996.
31. Shay, J. W., and Wright, W. E. The reactivation of telomerase activity in cancer progression TIG (Trends Genet.), 12: 129-130, 1996
32. Merlo, A, German, J. G , Mao, L., Lee, D. J., Gabrielson, E , Burger, P. C., Baylin, S. B , and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med., 1: 686-692, 1995.
33. Gozale-Zulueta, M , Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Turnout, J M., and Jones, P. A. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing Cancer Res , 55: 4531-4535, 1995.